Live Feeds
● TRACKER Updated 8d ago · 38 sources tracked

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Eli Lilly reported third-quarter revenue of $24.4 billion, a 39% increase driven by soaring sales of obesity treatment Zepbound and diabetes drug Mounjaro. Chair and CEO Dave Ricks announced the earnings growth during the Q3 earnings call, prompting the pharmaceutical company to raise its full-year outlook. Shares rose 4% in early morning trading following the announcement. The strong financial performance reflects intense market demand for the company's incretin medications as manufacturing efforts scale up globally to address supply constraints.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (42)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Eli Lilly reported third-quarter revenue of $24.4 billion.
  • ✓ Third-quarter revenue grew 39% from the prior-year period.
  • ✓ Growth was driven primarily by demand for Mounjaro and Zepbound incretin medicines and continued growth across international markets.
  • ✓ Eli Lilly shares rose 4% in early morning trading following the earnings report.
🛡️ Source Corroboration: 38 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Eli Lilly reported its Q3 2026 financial results, revealing a 39% revenue increase and leading management to raise the full-year outlook.

Live updates

  1. Eli Lilly Q3 Revenue Jumps 39% Amid High GLP-1 Demand

    Eli Lilly reported third-quarter revenue of $24.4 billion, a 39% increase driven by soaring sales of obesity treatment Zepbound and diabetes drug Mounjaro. Chair and CEO Dave Ricks announced the earnings growth during the Q3 earnings call, prompting the pharmaceutical company to raise its full-year outlook. Shares rose 4% in early morning trading following the announcement. The strong financial performance reflects intense market demand for the company's incretin medications as manufacturing efforts scale up globally to address supply constraints.

    Why it matters

    The surging sales underscore the dominant market position of Eli Lilly in the burgeoning weight-loss and diabetes treatment sector. Robust international demand for flagship products Mounjaro and Zepbound has fueled consecutive quarters of substantial financial gains. The company is currently expanding its manufacturing footprint domestically and internationally to keep pace with consumption.

    What is confirmed

    • Eli Lilly reported third-quarter revenue of $24.4 billion.
    • Third-quarter revenue grew 39% from the prior-year period.
    • Growth was driven primarily by demand for Mounjaro and Zepbound incretin medicines and continued growth across international markets.
    • Eli Lilly shares rose 4% in early morning trading following the earnings report.
    • Chair and CEO Dave Ricks stated that Eli Lilly raised its full-year outlook.

    What to watch next

    • Full-year financial performance relative to the raised guidance
    • Further updates on manufacturing facility construction timelines across the United States
    • Final European regulatory decisions regarding the once-daily weight-loss pill
    Sources used for this update (4)
    1. www.cnbc.com — UnitedHealth is finally getting its act together. I'm buying ...
    2. www.cnbc.com — Eli Lilly (LLY) earnings Q3 2026 - CNBC
    3. www.biospace.com — Lilly can’t stop, won’t stop as revenue climbs 39% thanks to ...
    4. finance.yahoo.com — What Eli Lilly and Company (LLY) Said on Its Q3 Earnings Call
    confidence 100%

  2. Eli Lilly Scaling GLP-1 Production as Foundayo Adoption Grows

    Eli Lilly CEO tells CNBC that one-third of new oral GLP-1 medication patients are taking Foundayo, matching prior reporting. The pharmaceutical company is ramping up manufacturing capabilities to meet surging market demand. Recent developments include a ground-breaking ceremony for a Houston oral GLP-1 manufacturing facility, which forms part of a broader plan to build ten plants across the United States. Meanwhile, the European Medicines Agency advisory committee recommended the once-daily weight-loss pill for approval, which would make it the second authorized GLP-1 pill in the European bloc.

    Why it matters

    Eli Lilly maintains a market advantage over competitor Novo Nordisk in the lucrative GLP-1 sector. Financial results for the second quarter demonstrated a revenue surge of 48 percent to reach $22.97 billion, pushing the company's total market value to approximately $1.02 trillion. Manufacturing expansion is critical for maintaining this trajectory as global demand for diabetes and weight-loss treatments accelerates.

    What is confirmed

    • One-third of new oral GLP-1 patients are taking Foundayo according to the Eli Lilly CEO speaking to CNBC.
    • Eli Lilly posted a second-quarter revenue rise of 48 percent to $22.97 billion.
    • Eli Lilly holds a market value of about $1.02 trillion.

    What to watch next

    • Final approval decision for Foundayo by the European Medicines Agency
    • Progress updates on the ten planned U.S. manufacturing facilities including the Houston site
    Sources used for this update (4)
    1. www.accio.com — Copper Concentrate Price 2026: Trends & Outlook - accio.com
    2. beebulletin.com — US Tariffs 2026: Current Rates and Price Impact
    3. www.accio.com — Trending Technology News July 2026: AI & Innovation
    4. finance.yahoo.com — Honeywell Technologies raises 2026 outlook due to data center ...
    confidence 100%

  3. Eli Lilly Expands Oral GLP-1 Production as Foundayo Nears EU Greenlight

    One-third of new patients starting an oral GLP-1 medication are selecting Foundayo as Eli Lilly ramps up manufacturing to meet demand. The European Medicines Agency advisory committee recommended the once-daily weight-loss pill for approval, positioning it to become the second GLP-1 pill authorized in the bloc. Eli Lilly recently broke ground on a Houston oral GLP-1 manufacturing site, marking one of ten planned facilities across the United States. Meanwhile, Eli Lilly leads competitor Novo Nordisk in GLP-1 medicines, posting a second-quarter revenue rise of 48 percent to $22.97 billion and a market value of about $1.02 trillion.

    Why it matters

    The pharmaceutical sector is experiencing intense competition in the obesity treatment market, where blockbuster revenues drive massive corporate valuations. Eli Lilly is scaling up its production capabilities with new domestic facilities to maintain its advantage over rival drugmakers like Novo Nordisk. Regulatory decisions in Europe and the United States will shape market share as both companies race to secure approvals for their respective oral weight-loss therapies.

    What is confirmed

    • Eli Lilly second-quarter revenue rose 48 percent to $22.97 billion, with a market value of about $1.02 trillion.
    • One-third of all new patients starting an oral GLP-1 medication are selecting Foundayo.
    • The European Medicines Agency advisory committee recommended Foundayo for approval.
    • Eli Lilly broke ground at a Houston oral GLP-1 manufacturing site as one of ten planned facilities in the United States.

    Still unconfirmed

    • Novo Nordisk expects an FDA decision on CagriSema in the fourth quarter of 2026 alongside its Wegovy pill.

    What to watch next

    • The formal European regulatory approval decision for Foundayo
    • Novo Nordisk's FDA decision on CagriSema expected in the fourth quarter of 2026
    • Eli Lilly's planned filing for retatrutide in the first quarter of 2027
    Sources used for this update (4)
    1. www.onedayadvisor.com — Eli Lilly vs. Novo Nordisk — The GLP‑1 Market Showdown (2026 ...
    2. 247wallst.com — Eli Lilly Rises 4% While Foundayo Nears European Approval ...
    3. www.bioxconomy.com — Eli Lilly breaks ground at Houston oral GLP-1 manufacturing site
    4. www.healthyoneapp.com — Foundayo Review 2026: Lilly's Orforglipron Pill, Results ...
    confidence 95%

  4. Eli Lilly's Foundayo Pill Wins European Regulatory Backing

    Eli Lilly CEO Dave Ricks reported that one-third of all new patients starting an oral GLP-1 medication are selecting Foundayo as production ramps up to meet demand. The European Medicines Agency advisory committee recommended the once-daily weight-loss pill for approval, positioning it to become the second GLP-1 pill authorized in the bloc. Fresh clinical data highlights the pill's performance against rivals while markets monitor pipeline updates for Foundayo, Zepbound, and retatrutide amid heavy revenue reliance on blockbuster treatments.

    Why it matters

    Eli Lilly depends on its blockbuster weight-loss and diabetes treatments for more than sixty percent of its revenue, creating concentration risk that makes pipeline expansion critical. Foundayo represents a key pillar in diversifying this portfolio alongside Zepbound and retatrutide. Regulatory clearance in Europe opens a major international market for the oral treatment following initial patient uptake in domestic channels.

    What is confirmed

    • The European Medicines Agency advisory committee recommended Eli Lilly's once-daily weight-loss pill Foundayo for approval.
    • Foundayo is set up to be the second GLP-1 pill approved in the European bloc.
    • One-third of all new patients starting an oral GLP-1 medication are selecting Foundayo, according to Eli Lilly CEO Dave Ricks.

    What to watch next

    • Formal European Union drug regulator approval for Foundayo
    • Upcoming Q3 financial results regarding GLP-1 portfolio sales
    • Further pipeline updates for Zepbound and retatrutide
    Sources used for this update (4)
    1. www.cnbc.com — Eli Lilly's weight-loss pill wins EU drug regulator's ... - CNBC
    2. finance.yahoo.com — How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 ...
    3. www.fool.com — Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's ...
    4. finance.yahoo.com — Lilly’s Foundayo Pill Gets European Regulatory Backing – LLY ...
    confidence 95%

  5. Eli Lilly CEO Reports One-Third of New GLP-1 Pill Patients Choose Foundayo

    One-third of all new patients starting an oral GLP-1 medication are selecting Foundayo, according to Eli Lilly CEO Dave Ricks. The company is actively ramping up production to meet demand as fresh clinical data highlights the pill's performance against rivals. Meanwhile, Eli Lilly faces the concentration risk of relying on blockbuster weight-loss and diabetes treatments for more than sixty percent of its revenue. Market attention remains focused on the drugmaker's pipeline updates for Foundayo, Zepbound, and retatrutide.

    Why it matters

    Eli Lilly has achieved substantial valuation milestones fueled by its dominant weight-loss and diabetes product lines, making it the first one-trillion-dollar pharma company. However, the heavy reliance on these specific medications introduces corporate risk that the management team must balance against surging global demand. Fresh clinical presentations in Milan have bolstered confidence in the pipeline, even as shares experience short-term volatility.

    What is confirmed

    • One-third of all new patients starting an oral GLP-1 medication are choosing Foundayo, according to Eli Lilly.
    • Eli Lilly CEO Dave Ricks built the company into a one-trillion-dollar pharma enterprise with blockbuster weight-loss and diabetes drugs.
    • More than sixty percent of Eli Lilly revenue comes from its weight-loss and diabetes treatments.
    • Fresh data on Zepbound, Foundayo, and retatrutide has reset market attention on the Eli Lilly pipeline.

    What to watch next

    • Updates on manufacturing capacity and production ramp timelines for Foundayo
    • Further clinical developments regarding retatrutide and Zepbound
    • Changes in share price performance and quarterly revenue concentration metrics
    Sources used for this update (6)
    1. www.glp1authority.com — GLP-1 News & Updates — Daily Summaries | GLP1Authority
    2. www.cnbc.com — Health and Science
    3. www.fool.com — This Drug Combination for Eli Lilly Generated Significantly ...
    4. finance.yahoo.com — Eli Lilly (LLY) As Zepbound And Retatrutide Updates Test ...
    5. finance.yahoo.com — GLP-1s Took Eli Lilly To $1 Trillion. CEO Dave Ricks Is ...
    6. health.yahoo.com — The Science Of Foundayo: How Eli Lilly’s Daily Weight Loss ...
    confidence 100%

  6. Eli Lilly Reports Strong Patient Adoption for Foundayo Oral GLP-1

    One-third of all new patients starting an oral GLP-1 medication are now choosing Foundayo, according to Eli Lilly. The drugmaker presented new data at the European Association for the Study of Diabetes meeting in Milan showing that Foundayo delivered greater weight loss and better blood sugar control than oral semaglutide 25 mg in adults with type 2 diabetes. And post-hoc analyses of the ATTAIN-1 study indicated that the oral medication, also known as orforglipron, was associated with significant reductions in the predicted long-term risk of type 2 diabetes and cardiovascular disease.

    Why it matters

    The commercial battle between major pharmaceutical players has intensified as companies roll out oral alternatives to traditional injectable treatments. Eli Lilly secured approval for Foundayo in April, following the January launch of oral Wegovy by rival drugmaker Novo Nordisk. These oral formulations are driving a broader transition from injectable-first to oral-first prescribing habits within the obesity and diabetes treatment markets.

    What is confirmed

    • One-third of all new patients starting an oral GLP-1 medication are now choosing Foundayo.
    • Eli Lilly presented data at the European Association for the Study of Diabetes meeting in Milan showing that Foundayo delivered greater weight loss and better blood sugar control than oral semaglutide 25 mg in adults with type 2 diabetes.
    • Lilly's oral GLP-1, Foundayo, was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease.

    Still unconfirmed

    • Novo Nordisk and Eli Lilly are building cases for switching patients to oral therapies during the maintenance phase after initial injectables.

    What to watch next

    • Commercial adoption rates of oral GLP-1 medications as manufacturing scales up
    • Upcoming regulatory decisions and filings for next-generation obesity treatments
    Sources used for this update (9)
    1. www.biospace.com — GLP-1 - BioSpace
    2. finance.yahoo.com — Eli Lilly’s Foundayo delivers diabetes surprise in late-stage ...
    3. www.prnewswire.com — Lilly's oral GLP-1, Foundayo (orforglipron), was associated ...
    4. www.onedaymd.com — GLP-1 2.0: The Next Generation of Obesity Drugs - onedaymd.com
    5. finance.yahoo.com — Eli Lilly Just Announced Something Big. Here’s What It Means ...
    6. pharmaphorum.com — Novo, Lilly trade oral GLP-1 data readouts at ECO
    7. peptidestaff.com — The Oral GLP-1 Race: How Novo Nordisk, Eli Lilly, and Pfizer ...
    8. peptidestaff.com — Oral GLP-1 Drugs Reshape the Obesity Market: How Novo Nordisk ...
    9. finance.yahoo.com — Foundayo Showed Better Results Than Oral Semaglutide in a New ...
    confidence 100%

  7. Eli Lilly Expands GLP-1 Production

    Eli Lilly continues to scale its manufacturing operations within the lucrative GLP-1 drug sector, capturing market share as competition intensifies with rival drugmaker Novo Nordisk. Foundayo remains a key component of the company's oral treatment offerings, though market analysts have previously noted varying paces in the rollout. Investors are closely tracking production updates and commercial strategies as both major pharmaceutical players vie for dominance in diabetes and obesity treatments. The company's ongoing manufacturing ramp-up aims to support growing patient demand across its expanding portfolio of specialized pharmaceutical treatments.

    Why it matters

    The pharmaceutical industry faces intense scrutiny as companies race to meet high global demand for advanced weight loss and diabetes medications. Manufacturing capacity remains a primary bottleneck and a key competitive advantage for market leaders like Eli Lilly and Novo Nordisk. Financial markets continue to evaluate strategic execution, commercial data, and production scaling announcements to gauge long-term profitability.

    What to watch next

    • Further announcements regarding production capacity milestones from Eli Lilly
    • Updates on the commercial rollout pace of Foundayo
    Sources used for this update (9)
    1. www.gotquestions.org — Who was Eli in the Bible? - GotQuestions.org
    2. elireview.com — Eli Review
    3. www.eli.org — ELI Home | Environmental Law Institute
    4. biblehub.com — Topical Bible: Eli
    5. www.fool.com — Eli Lilly's weight loss drug business
    6. en.wikipedia.org — Eli (2019 film) - Wikipedia
    7. en.wikipedia.org — Eli (biblical figure) - Wikipedia
    8. www.youtube.com — Eli | Official Trailer | Netflix - YouTube
    9. www.eli.edu — ELI
    confidence 20%

  8. Novo unveils growth strategy while Eli Lilly expands GLP-1 lead

    Eli Lilly continues to gain ground in the GLP-1 obesity and diabetes drug market, driven by its oral treatment Foundayo. Although BMO Capital Markets described the rollout of Foundayo as slower-than-hoped, the company is using indirect comparison data to build its commercial case. Meanwhile, rival drugmaker Novo Nordisk presented an ambitious growth strategy at its Capital Markets Day. However, investors remained skeptical about Novo's positioning as Eli Lilly advances its market share and manufacturing scale in the lucrative sector.

    Why it matters

    The intensifying competition between Eli Lilly and Novo Nordisk highlights the high-stakes race for dominance in the obesity and diabetes treatment market. Oral GLP-1 medications like Foundayo represent a major new frontier for pharmaceutical firms trying to capture expanding patient demographics. Analysts are closely watching how both companies scale production and market their products to investors who remain sensitive to shifts in market share.

    What is confirmed

    • Novo Nordisk outlined an ambitious growth strategy at its Capital Markets Day.
    • Eli Lilly continues gaining market share in the GLP-1 obesity and diabetes drug space.

    Still unconfirmed

    • Eli Lilly's weight loss pill Foundayo has experienced a slower-than-hoped launch, according to BMO Capital Markets.
    • Indirect comparison data could help Eli Lilly build commercial momentum for Foundayo despite falling short of definitive proof of superiority.
    • Investors remained skeptical of Novo Nordisk during its Capital Markets Day presentation as Eli Lilly gains ground.

    What to watch next

    • Investor reaction and stock performance following Novo Nordisk's Capital Markets Day
    • Sales performance and adoption rates for Eli Lilly's Foundayo
    Sources used for this update (3)
    1. rocketnews.com — Novo is betting on its next chapter as Eli Lilly gains more ...
    2. www.cnbc.com — Biotechnology and Pharmaceuticals - CNBC
    3. www.biospace.com — Lilly builds commercial case for GLP-1 products over Novo ...
    confidence 90%

  9. Eli Lilly CEO Says Foundayo Captures One-Third of New Oral GLP-1 Patients

    Eli Lilly Chief Executive Officer David Ricks reports that Foundayo accounts for approximately one-third of new patients beginning oral GLP-1 treatments, with market share increasing weekly. The commercial momentum coincides with a broader expansion into senior demographics following recent Medicare coverage changes. To support long-term manufacturing needs, the drugmaker broke ground on a multi-billion-dollar facility in Houston. Meanwhile, competitor Novo is pursuing its own capacity scale-up and turnaround efforts as analysts assess market positioning in the lucrative obesity treatment sector.

    Why it matters

    Medicare began covering obesity drugs in July, prompting a temporary Bridge program that allows eligible beneficiaries to obtain treatments for a $50 monthly co-pay. This policy shift opened a massive new wave of patients into the market. Eli Lilly secured a dominant early position among these beneficiaries, capturing a large majority of the newly treated senior population.

    What is confirmed

    • Eli Lilly CEO David Ricks stated that about 700,000 new seniors have started GLP-1 treatment since Medicare began covering obesity drugs.
    • Roughly 70 percent of the new senior patients on GLP-1 medications are using Lilly medicines.
    • Foundayo accounts for roughly one-third of new patients starting an oral GLP-1.
    • Eli Lilly broke ground on a $6.5 billion manufacturing facility in Houston.

    Still unconfirmed

    • Some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

    What to watch next

    • Execution and capacity scaling at the newly broken ground $6.5 billion Houston manufacturing facility
    • Market share shifts between Eli Lilly and rival Novo as oral GLP-1 production expands
    Sources used for this update (7)
    1. www.cnbc.com — Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
    2. finance.yahoo.com — A New Wave of Senior Patients Could Extend Lilly’s GLP-1 ...
    3. finance.yahoo.com — Lilly’s Oral GLP-1 Push Gains Momentum. Can Foundayo Become ...
    4. rocketnews.com — Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients ...
    5. www.cnbc.com — Companies - CNBC
    6. biotechresearch.co.uk — Lilly Houston $6.5B Plant & Novo Capital Markets Day: Oral ...
    7. www.el-fondo.com — Lilly Captures 70% of New Medicare GLP-1 Patients
    confidence 100%

  10. Eli Lilly CEO Reports Strong Initial Uptake for Foundayo

    One-third of new patients starting on oral GLP-1 weight-loss medications are taking Eli Lilly drug Foundayo, according to company Chief Executive Officer Dave Ricks. The strong market adoption comes as the drugmaker actively ramps up production to meet surging demand in the lucrative obesity and weight-loss treatment sector. Alongside the commercial performance of its pill, Eli Lilly announced broader portfolio strength, noting that 70 percent of 700,000 new seniors starting GLP-1 medications following Medicare coverage are using Lilly products. To support long-term manufacturing needs, the company broke ground on a massive facility in Houston.

    Why it matters

    The weight-loss drug market has expanded rapidly, prompting heavy investments and infrastructure buildouts from major developers. Eli Lilly is investing billions of dollars in new production sites across the United States to secure supply chains for its popular therapies. These manufacturing expansions aim to address chronic supply constraints that have historically affected the entire class of incretin-based treatments.

    What is confirmed

    • One-third of new GLP-1 pill patients are taking Foundayo, according to Eli Lilly CEO Dave Ricks.
    • Foundayo has captured over 30% of new US patients on oral weight-loss drugs.
    • Eli Lilly broke ground on a $6.5 billion plant in Houston.
    • Seventy percent of 700,000 new seniors who started GLP-1s after Medicare coverage are on Lilly drugs, according to the CEO.

    What to watch next

    • Expansion of Foundayo into foreign markets as noted by CEO Dave Ricks
    • Progress on the Houston manufacturing facility slated for 2030
    Sources used for this update (13)
    1. CNBC — Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
    2. Reuters — Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs
    3. Investing.com — Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up By Reuters
    4. TipRanks — Eli Lilly Stock (LLY) Rises After Company Provides Update on Obesity Pill Sales
    5. TradingView — Eli Lilly CEO Ricks sees more Foundayo growth with foreign markets
    6. KHOU — Eli Lilly is breaking ground in Houston on a facility planned for 2030
    7. houstonchronicle.com — The company behind a new GLP-1 pill is betting $6.5 billion on Houston
    8. qz.com — Lilly CEO Dave Ricks says Foundayo winning new pill patients
    9. Reuters — Weight-loss drug developers line up to tap lucrative market as competition heats up
    10. Axios — Eli Lilly breaks ground on $6.5B Houston plant
    11. CNBC — Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
    12. abc13.com — Lilly breaks ground in Generation Park, announces $15M contribution to San Jacinto College
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community